The ABLIM1 Knockout Jurkat Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Jurkat T lymphoblast cell line, designed to disrupt the expression of the actin-binding LIM protein 1 (ABLIM1). This polyclonal pool offers a heterogeneous loss-of-function model that recapitulates the genetic deletion of ABLIM1 across a bulk cell population, enabling robust functional studies without the clonal artifacts associated with single-cell-derived knockout lines. The product facilitates investigation of ABLIM1-dependent mechanisms in a T-cell context, particularly those involving cytoskeletal regulation and adhesion dynamics.
The parental Jurkat cell line is an immortalized human T lymphoblast line originally isolated from the peripheral blood of a 14-year-old male with acute T cell leukemia. Jurkat cells grow in suspension and have been extensively employed as a model system to elucidate T cell receptor (TCR) signaling, apoptosis, and immune activation pathways. Their ease of culture and well-characterized signaling network make them a preferred host for gene perturbation studies aimed at dissecting molecular determinants of T cell function and dysfunction.
ABLIM1 encodes an actin-binding protein featuring multiple LIM domains and a villin headpiece domain, which collectively mediate interactions with the actin cytoskeleton and contribute to the regulation of cell adhesion and migration. Within T cells, ABLIM1 functions downstream of integrin engagement and is regulated by Rho family GTPases such as RhoA and Rac1, as well as by focal adhesion kinase (FAK). It associates with F-actin, ??-catenin, and the adaptor protein Talin, and is postulated to interact with LMO2. Through these interactions, ABLIM1 coordinates actin polymerization, focal adhesion assembly, and the cellular machinery required for directed migration, thereby linking extracellular matrix cues to cytoskeletal remodeling.
Disruption of ABLIM1 in Jurkat cells profoundly impacts actin cytoskeletal organization at both adhesion sites and the immune synapse. Consequently, ABLIM1 knockout polyclonal cells exhibit impaired T cell adhesion to integrin ligands, reduced migratory capacity, and altered TCR-induced signaling cascades. This model therefore provides a physiologically relevant platform to dissect how actin-binding adaptors translate integrin-mediated signals into functional outcomes such as immunological synapse formation and T cell activation, shedding light on mechanisms that may be dysregulated in immune disorders and cancer.
These polyclonal knockout cells are suited for a range of experimental approaches, including western blotting to confirm loss of ABLIM1 protein, immunofluorescence microscopy to visualize cytoskeletal defects, cell adhesion assays on integrin ??V??3 substrates, and Transwell migration assays to quantify chemotactic responses. Additionally, flow cytometric analysis of activation markers such as CD69 and CD25, coupled with phospho-signaling assessments by flow cytometry, can be employed to evaluate TCR signaling competency. For further details and ordering information, please contact Ascent Research.
